Stephen Aselage compensation by year
Travere Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $510,417 | $552,570 | $593,333 | $76,151 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $649,200 | $795,000 | $1,312,844 | $0 |
| Option awards | $1,567,712 | $1,845,855 | $2,356,660 | $0 |
| Non-equity incentive | $263,415 | $226,800 | $331,200 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $7,950 | $8,100 | $8,250 | $963,118 |
| Total | $2,998,694 | $3,428,325 | $4,602,287 | $1,039,269 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 14, 2020, accession 0001438533-20-000007, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-20-000007. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 40,000 | $568,000 | — |
| PSU | 20,625 | $292,875 | — |
| PSU | 18,500 | $262,700 | — |
| PSU | 18,375 | $260,925 | — |
| PSU | 12,250 | $173,950 | — |
| PSU | 2,000 | $28,400 | — |
| Option | 8,000 | — | $17.94 |
| Option | 61,875 | — | $17.44 |
| Option | 88,813 | — | $25.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Travere Therapeutics’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $9,679,319 |
| Noah Rosenberg | Former Chief Medical Officer | $1,369,643 |
| Peter Heerma | Chief Commercial Officer | $1,325,278 |
| William Rote | Senior Vice President and Head of Research and Development | $1,310,226 |
| Laura Clague | Senior Vice President and Chief Financial Officer | $1,303,582 |
| Elizabeth Reed | Senior Vice President, General Counsel and Corporate Secretary | $1,258,447 |
| Stephen Aselage · this page | Director and Former President and Chief Executive Officer | $1,039,269 |
Board service
Travere Therapeutics board · FY2021–FY2022| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2022 | $41,250 | $3,200,000 | $0 | — | $3,241,250 |
| FY2021 | $55,000 | $54,810 | $164,430 | — | $274,240 |
Each year as the company reported it in Travere Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Travere Therapeutics pays directors a $50,000 cash retainer. As stated in Travere Therapeutics's FY2022 proxy.
The full Travere Therapeutics compensation record
free company briefThis page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Travere Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.